
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd has demonstrated significant growth in its financial performance, reporting a fourth-quarter revenue of $161.3 million, which reflects a 4% increase from the previous quarter, and a full-year revenue of $605.2 million, marking a 19% increase compared to 2023. The company's positive outlook is further supported by a strong increase in the probability of success (POS) for its pancreatic cancer treatments, rising from 20% to 70% after favorable trial results, which adds confidence in its pipeline. Additionally, the recent approvals of the new HFE transducer arrays enhance the usability and appeal of the Optune Gio device, potentially increasing patient compliance and leading to improved long-term survival rates, thereby strengthening NovoCure's market position in oncology.
Bears say
NovoCure Ltd has revised its 2025 revenue estimate down to $616.1 million from a prior estimate of $648.1 million, reflecting anticipated low-to-mid single-digit growth that does not account for improvements in approval rates. The company has also reported a 4% decline in prescriptions for its Optune Gio device in the fourth quarter of 2024, indicating potential challenges in product adoption and market penetration. Additionally, there are multiple risks that could negatively impact the company's performance, including safety concerns in clinical programs, lower-than-expected efficacy, increasing competition, regulatory challenges, and issues related to intellectual property protection.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares